MARKET

KTOV

KTOV

Kitov Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.990
-0.080
-1.97%
After Hours: 3.990 0 0.00% 17:59 09/24 EDT
OPEN
3.950
PREV CLOSE
4.070
HIGH
4.100
LOW
3.799
VOLUME
487.17K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
2.200
MARKET CAP
68.67M
P/E (TTM)
-0.0317
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dosing underway in Kitov Pharma's NT219 study in advanced cancer patients
Kitov Pharma (KTOV) announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in
Seekingalpha · 09/08 12:02
Kitov Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of NT219 In Advanced Cancer Patients
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug
Benzinga · 09/08 11:15
Kitov Pharma On Sept. 4 Received Notification Letter From Nasdaq Stating Co. Has Regained Compliance
On September 4, 2020, Kitov Pharma Ltd. (the “Company”) received a notification letter from Nasdaq stating that Nasdaq has determined that for ten consecutive business days (from August 21, 2020 through
Benzinga · 09/08 10:40
Kitov Pharma receives new patents for CM24 and NT219 in China
Kitov Pharma (KTOV) announces receipt of notification from the Chinese Patent Office to grant two separate patents for its lead oncology candidates CM24, a monoclonal antibody targeting CEACAM1, and NT219,
Seekingalpha · 09/04 12:43
PDD, GAN among premarket losers
Seeking Alpha - Article · 08/21 12:19
Kitov Pharma announces ADS ratio change
Seeking Alpha - Article · 08/13 13:36
Kitov Pharma Announces ADS Ratio Change
GlobeNewswire · 08/12 21:55
Kitov Pharma To Change ADS Ratio From 1-To-1 To 1-To-10
Benzinga · 08/12 20:56
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTOV. Analyze the recent business situations of Kitov Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTOV stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 512.08K
% Owned: 2.98%
Shares Outstanding: 17.21M
TypeInstitutionsShares
Increased
4
58.47K
New
27
-202.97K
Decreased
3
68.42K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.18%
Pharmaceuticals & Medical Research
-0.91%
Key Executives
Chairman/Director
John Waymack
Chief Executive Officer/Director
Itzhak Israel
Chief Financial Officer/Director
Simcha Rock
Vice President - Business Development
Gil Ben-Menachem
General Counsel/Secretary
Avraham Ben-Tzvi
Other
Yisrael Gewirtz
Other
Hadas Reuveni
Independent Director
Ido Agmon
Non-Executive Director
Alain Zeitoun
Independent Director
Steven Steinberg
Independent Director
Philip Serlin
Independent Director
Revital Stern-Raff
Independent Director
Ran Tzror
Independent Director
Arie Weber
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KTOV
Kitov Pharma Ltd, formerly Kitov Pharmaceuticals Holdings Ltd, is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kitov Pharma Ltd stock information, including NASDAQ:KTOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTOV stock methods without spending real money on the virtual paper trading platform.